ZARR

News and price dashboard

Swept 22:00
Sources
27, all reachable
Items
76449
Flagged
9588
Last swept
22:00

STOCKS

121

OPTIONS

25

COMING UP

US majors and your names' earnings, next 7 days

Full calendar

Everything else — unscored, browse only, never pushed

Brief

Feed shape today

This is the unfiltered general feed: 200 items, and the overwhelming majority are routine Investing.com 8-K notices, Form 4 insider filings, TradingView chart posts and Nasdaq option-activity screens with no substance behind them. Twenty were read in full, and of those, most are the same automated "stock hits 52-week high/low" template run twice across the UK and US editions of Investing.com, so the duplicate pairs are one story each, not two.

A cluster of 52-week lows

The biggest single theme in the read items is a run of new 52-week lows. T-Mobile hit $147.89, down 32% over the year and 34.5% off its $225.93 high, with the ticker line showing TMUS down 7.70%. The article gives no reason for the day's drop, but notes earnings due October 28 and a string of recent broker notes: Raymond James upgraded to Outperform arguing SpaceX competition fears are overdone, KeyBanc stayed Overweight on possible upside in average revenue per account despite slightly higher churn from pricing actions, StoneX reiterated Buy on AI implementation, and JPMorgan cut its target to $260 from $275 while keeping Overweight and trimming revenue estimates to line up with T-Mobile's $19.30bn wireless service revenue guidance. NewAmsterdam Pharma touched $19.55, down 44.92% on the year with the ticker showing NAMS off 8.67%, against a $2.35bn market cap; the piece cites EU approval of its obicetrapib/ezetimibe fixed-dose combination, Stifel holding Buy and a $50 target after the failure of Novartis's HORIZON trial, RBC cutting to $42 from $50 over the Phase III PREVAIL interim analysis at a 35-38% estimated probability of success, and CEO Michael Davidson buying 10,000 shares for $226,500. MGM Resorts hit $27.93 against a $51.59 high, shown down 4.97%, with earnings five days out; the context given is Macau gaming revenue projected by Jefferies to fall 6-10% in October, a $107m room renovation disrupting Borgata, and Mizuho cutting its target to $55 from $60 after People Inc. withdrew its bid for the shares it doesn't own. Two more lows are quieter: Huntington Bancshares' 4.500% Series H preferred at $14.90, down 18.73% over the year on a 7.51% yield and a 56-year dividend record, and Selective Insurance Group's SIGIP preferred at $14.74, down 16.42%, yielding 7.75% with 52 straight years of dividends. Neither article gives a specific cause beyond general rate and financial-sector pressure.

The two highs, and what's behind them

Going the other way, Amerant Bancorp hit a 52-week high of $30.65, up 77.42% over a year and 53.72% year to date on a $1.2bn market cap, after Q3 2026 diluted EPS of $0.65 against the $0.57 consensus, revenue of $108.8m versus $103.35m expected, net income of $25.7m and a 1.0% return on assets, its best on that measure since 2022. Safety Insurance Group set an all-time high at $104.16, up 56% over the year, and the reason is specific: the Hart-Scott-Rodino waiting period on its merger with MAPFRE U.S.A. has expired, clearing a condition for the deal announced on 23 July 2026, under which Splash Merger Sub merges into Safety and the company becomes a MAPFRE subsidiary.

Macy's dividend

The only other full-text item with real content is Macy's declaring a regular quarterly dividend of 19.15 cents per share, payable 4 January 2027 to holders of record on 15 December 2026.

Filings with nothing attached

Four full-text items turned out to be bare 8-K notices with no body text at all: Ionis Pharmaceuticals, Zevia, Unity Software and Visa, all dated 23 October. There is nothing in them to read beyond the fact that a filing exists.

What the headline-only remainder contains

The rest is headlines only, so take them as stated and nothing more. Earnings coverage runs through regional banks and REITs: Preferred Bank beat on Q3 EPS with shares slipping premarket, First Hawaiian missed as shares fell with NIM gains offset by credit costs, WSFS beat with wealth revenue up 30% and ROTCE at 20.7%, and Kilroy Realty raised guidance on record leasing. On biotech, Roche's sefaxersen is reported to have shown a 43% proteinuria reduction in an IgA nephropathy trial, with Ionis named as partner, Vertex reported positive IgAN data with an FDA decision due 30 November, and the FDA approved a subcutaneous induction regimen for AbbVie's Skyrizi. Several analyst headlines sit unread: Jefferies raising Zymeworks on the Roche deal, Williams Trading cutting Deckers on weak DTC trends, RBC reiterating Outperform on Verisk, and Raymond James reiterating Strong Buy on Alnylam. On trade, two separate headlines say the US is expected to lift 50% tariffs on some Canadian agricultural and forestry goods, one framing it as relief for trade-dependent states. Commodities headlines point to cocoa falling on rising ICE inventories and higher Nigerian exports, coffee falling despite inventories at a five-week low, sugar supported by lower Brazilian production, and Indian crude imports up 16% in September. The remainder is chart-idea posts, option-activity screens, consensus-target adjustments and political social media, none of which carries anything beyond its own title.

20 read in full, 200 items in the section

Feed

145 stories · 145 newCross-publisher stories only